Deckert, J
Weber, H
Villmann, C
Lonsdorf, T B
Richter, J
Andreatta, M
Arias-Vasquez, A
Hommers, L
Kent, L
Schartner, C
Cichon, S
Wolf, C
Schaefer, N
von Collenberg, C R
Wachter, B
Blum, R
Schümann, D
Scharfenort, R
Schumacher, J
Forstner, A J
Baumann, C
Schiele, M A
Notzon, S
Zwanzger, P
Janzing, J G E
Galesloot, T
Kiemeney, L A
Gajewska, A
Glotzbach-Schoon, E
Mühlberger, A
Alpers, G
Fydrich, T
Fehm, L
Gerlach, A L
Kircher, T
Lang, T
Ströhle, A
Arolt, V
Wittchen, H-U
Kalisch, R
Büchel, C
Hamm, A
Nöthen, M M
Romanos, M
Domschke, K
Pauli, P
Reif, A
Article History
Received: 3 May 2016
Revised: 12 December 2016
Accepted: 19 December 2016
First Online: 7 February 2017
Competing interests
: Over the last 3 years, V Arolt has been a member of the advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Eli Lilly, Janssen-Organon, Lundbeck, Otsuka, Servier and Trommsdorff. He also received sponsorships for symposia and educational activities from Astra-Zeneca, Jansen-Organon, Lundbeck and Servier. C Büchel received speaker's honoraria from Janssen. K Domschke has received a honorarium for a scientific talk from Hexal. T Kircher received fees for educational programs from Janssen, Eli Lilly, Servier, Lundbeck, Bristol Myers Squibb, Pfizer and Astra-Zeneca. P Pauli and A Mühlberger are shareholders of a commercial company that develops virtual environment research systems for empirical studies in the field of psychology, psychiatry and psychotherapy. A Ströhle received research funding from Lundbeck, and speaker honoraria from Astra-Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly & Co, Lundbeck, Pfizer, Wyeth and UCB. He was a consultant for Actelion. Educational grants were given by the Boehringer Ingelheim Fonds, the Eli Lilly International Foundation, Janssen-Cilag, Pfizer and Eli Lilly & Co. H-U Wittchen has served as a general consultant (non-product related) for Pfizer, Lundbeck, Organon, Servier and Essex Pharma and has received grant funding for his institution from Sanofi Aventis, Pfizer, Lundbeck, Novatis, Essex Pharma, Servier and Wyeth. These cooperations have no relevance to the work that is covered in the manuscript. The remaining authors declare no conflict of interest.